Arecor Therapeutics PLC (AREC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arecor Therapeutics PLC (AREC) has a cash flow conversion efficiency ratio of -0.400x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.14 Million ≈ $-139.07 USD) by net assets (GBX2.86 Million ≈ $347.49 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arecor Therapeutics PLC - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Arecor Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Arecor Therapeutics PLC carry for a breakdown of total debt and financial obligations.
Arecor Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arecor Therapeutics PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bolt Projects Holdings, Inc.
NASDAQ:BSLK
|
-0.024x |
|
FOXO Technologies Inc.
NYSE MKT:FOXO
|
-0.002x |
|
International Zeolite Corp
V:IZ
|
-0.053x |
|
ENGAGE XR HLDGS EO-001
F:6VR
|
N/A |
|
Capital Metals PLC
LSE:CMET
|
-0.094x |
|
Petro Matad Ltd
LSE:MATD
|
-0.040x |
|
SCRYB INC.
F:EIY
|
N/A |
|
Wag! Group Co.
NASDAQ:PET
|
0.332x |
Annual Cash Flow Conversion Efficiency for Arecor Therapeutics PLC (2018–2024)
The table below shows the annual cash flow conversion efficiency of Arecor Therapeutics PLC from 2018 to 2024. For the full company profile with market capitalisation and key ratios, see Arecor Therapeutics PLC (AREC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX5.35 Million ≈ $650.82 |
GBX-9.15 Million ≈ $-1.11K |
-1.712x | -179.16% |
| 2023-12-31 | GBX9.53 Million ≈ $1.16K |
GBX-5.84 Million ≈ $-710.68 |
-0.613x | +0.73% |
| 2022-12-31 | GBX17.45 Million ≈ $2.12K |
GBX-10.78 Million ≈ $-1.31K |
-0.618x | -110.20% |
| 2021-12-31 | GBX18.55 Million ≈ $2.26K |
GBX-5.45 Million ≈ $-663.11 |
-0.294x | +87.75% |
| 2020-12-31 | GBX773.79K ≈ $94.15 |
GBX-1.86 Million ≈ $-225.90 |
-2.399x | -1577.65% |
| 2019-12-31 | GBX3.21 Million ≈ $390.31 |
GBX-458.80K ≈ $-55.82 |
-0.143x | +75.93% |
| 2019-05-31 | GBX4.22 Million ≈ $512.95 |
GBX-2.50 Million ≈ $-304.76 |
-0.594x | +19.14% |
| 2018-05-31 | GBX670.33K ≈ $81.56 |
GBX-492.57K ≈ $-59.93 |
-0.735x | -- |
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops innovative medicines that address significant unmet patient needs in the United Kingdom. The company through its proprietary reformulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deli… Read more